KOD — Kodiak Sciences Share News
0.000.00%
Last trade - 00:00Brief: Kodiak Sciences Says Jason Ehrlich Informed Co Of His Resignation As Chief Medical Officer And Chief Development Officer Of Co
Brief: Kodiak Sciences Inc - Still Evaluating A Variety Of Future Options For Tarcocimab Program
Kodiak Sciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Kodiak Sciences Q2 Net Income USD -80.188 Million
Kodiak Sciences Inc expected to post a loss of $1.14 a share - Earnings Preview
Kodiak Sciences Inc expected to post a loss of $1.14 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Huntington Bancshares, Kodiak Sciences, Prokidney
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX
U.S. STOCKS ON THE MOVE-PaxMedica, Heron, Belite Bio
Kodiak Sciences slumps as co scraps development of lead drug
U.S. STOCKS ON THE MOVE-Apple, Quince, Syndax Pharma
Kodiak Sciences scraps development of eye drug (updated)
U.S. STOCKS ON THE MOVE-Mattel, AMC, Nikola
Kodiak Sciences slumps on plan to scrap lead drug development
Kodiak Sciences scraps development of eye disorder drug (updated)
Kodiak Sciences scraps development of eye disorder drug
Brief: Kodiak Sciences Announces Topline Results From Its Phase 3 Studies Of Tarcocimab Tedromer In Neovascular Age-Related Macular Degeneration And Diabetic Macular Edema
Kodiak Sciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Kodiak Sciences Inc Files For Mixed Shelf Of Up To $350 Million - SEC Filing